Navigation Links
An Evaluation of Clinical Trial Quality in Russia and Ukraine, new webinar hosted by Xtalks
Date:3/8/2013

Toronto, Canada (PRWEB) March 08, 2013

With patient recruitment rates up to twenty times faster than the West, the biopharmaceutical industry is embracing the undeniable benefits of conducting clinical trials in emerging markets such as Russia. In fact, 33% of all drugs approved by the FDA and 48% of all drugs approved by the EMEA in 2011 included data from clinical trial research conducted in this region.

Yet with benefits like this, why isn’t this number closer to 100%? For many, the enticement for conducting clinical trials in emerging markets is over shadowed by the fear of unknown regulatory and logistics requirements, prolonged study start-up times and overall clinical trial quality.

During the webinar, ClinStar CEO David Passov and QA Director Dr. Stanislav Gneushev will evaluate the quality of clinical trials being conducted in Russia / Ukraine compared to Western Europe, Eastern Europe and other Emerging Markets based on the results of recent FDA inspections conducted at clinical trial sites in these regions. In addition, they will:

  •     Discuss key elements of successful Quality Management Systems for niche CROs operating in Russia, Ukraine, Belarus and the Baltics
  •     Provide practical advice on SOP development
  •     Present training approaches for optimal coaching of clinical monitors
  •     Consider what quality assurance activities are required in Russia and parts of Eastern Europe to ensure continuous quality improvement of clinical studies

For more information about this event or to register, visit: http://xtks.in/xto580-event

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/3/prweb10499405.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PhaseRx Announces Technology Evaluation Agreement with Monsanto
2. Evaluation of a Single 1.000 mg Iron Dose as Ferric Carboxymaltose (FCM) for Fatigue Treatment in Iron Deficient Women - PREFER
3. New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation
4. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
5. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
6. Macrogen Corp. Announces the Inception of Macrogen Clinical Laboratory (MCL)
7. PhUSE Announces Open Source Repository of Clinical Trial Informatics Analysis Code
8. QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics
9. NeoClinical Launches Neo PayPerPatient Clinical Trial Recruitment
10. Eastern Clinical Trials Russia CRO Passes EMA Inspection
11. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
(Date:2/23/2017)... SAN JOSE, Calif. , Feb. 23, 2017 ... an exclusive license for two key immunotherapy technologies ... The first technology provides a method to monitor ... therapy such as PD-L1 and CTLA-4.  The second ... detect if a patient is likely to have ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... in a published evaluation of multiple immunoassay-based threat detection technologies by researchers ... Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have the ...
(Date:2/23/2017)... 23, 2017 Aviva Systems Biology Corporation ... acquisition of GenWay Biotech Incorporated, a protein solutions ... product offering for both the research and diagnostic ... and enhance capabilities for both entities. GenWay,s 18 years ... will nicely complement ASB,s objective to become a ...
Breaking Biology Technology:
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):